window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

TRD

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression

    Alto Neuroscience has started a Phase 2b trial of ALTO-207 [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Compass Pathways reports positive second Phase 3 trial for COMP360 in treatment-resistant depression

    Compass Pathways has reported that its second pivotal Phase 3 [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference

    FundaMental Pharma GmbH will present new preclinical data on its [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CuraCell reports pancreatic cancer findings from personalised TIL therapy programme
    Categories: Advanced Therapies, Clinical & Regulatory, Therapeutic Areas
  • Nebu~Flow secures £2M Scottish Enterprise grant for nebuliser technology
    Categories: Drug Delivery & Formulation, Medical devices, Pharmaceuticals and therapeutics
  • Apoha raises $36M to expand molecular behaviour data platform
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top